מקדם חוב לטווח ארוך להון Zentalis Pharma (ZNTL)

Zentalis Pharmaceuticals (ZNTL) operates within a stable US legal framework with low geopolitical risk. The long-term debt-to-equity ratio visualizes this balance, with the current value standing at 0.24. The company is competing for the breast cancer targeted therapy market, leveraging its clinical successes. The financial profile remains resilient to macro cycles, as demand for oncology drugs is driven by critical medical necessity.

Zentalis Pharmaceuticals (ZNTL) oncology drug development involves significant regulatory risks and colossal clinical trial costs. The metric is calculated as the ratio of long-term liabilities to total equity, determining the business's degree of dependence on external financing. This indicator measures financial stability by showing the share of long-term loans within the asset structure. Low values confirm a priority for secondary offerings over debt capital. By analyzing the ratio of long-term debt to equity, an investor assesses the available financial leverage.